Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.

May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M; Antiretroviral Therapy (ART) Cohort Collaboration.

AIDS. 2007 May 31;21(9):1185-97.

2.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration.

Lancet. 2002 Jul 13;360(9327):119-29. Erratum in: Lancet 2002 Oct 12;360(9340):1178.

PMID:
12126821
3.

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.

Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort Collaboration.

Lancet. 2003 Aug 30;362(9385):679-86.

PMID:
12957089
5.

Mortality and progression to AIDS after starting highly active antiretroviral therapy.

van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group.

AIDS. 2003 Oct 17;17(15):2227-36.

PMID:
14523280
6.

Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.

Antiretroviral Therapy Cohort Collaboration, Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M.

Int J Epidemiol. 2009 Dec;38(6):1624-33. doi: 10.1093/ije/dyp306. Epub 2009 Oct 9.

7.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
8.
9.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR.

Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Review.

10.
11.

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M; Antiretroviral Therapy (ART) Cohort Collaboration.

Lancet. 2006 Aug 5;368(9534):451-8. Review.

PMID:
16890831
12.

Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.

Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2007 Mar;8(2):75-9.

13.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
14.

The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.

d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M; Antiretroviral Therapy Cohort Collaboration.

Arch Intern Med. 2005 Feb 28;165(4):416-23. Erratum in: Arch Intern Med. 2005 May 23;165(10):1200.

PMID:
15738371
15.

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S; CoRIS-MD.

PLoS One. 2006 Dec 20;1:e89.

17.

Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.

Anastos K, Barrón Y, Miotti P, Weiser B, Young M, Hessol N, Greenblatt RM, Cohen M, Augenbraun M, Levine A, Muñoz A; Women's Interagency HIV Study Collaborative Study Group.

Arch Intern Med. 2002 Sep 23;162(17):1973-80.

PMID:
12230420
18.
19.

Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.

Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.

AIDS. 2006 May 12;20(8):1171-9.

PMID:
16691069
20.

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group.

HIV Med. 2007 Mar;8(2):96-104.

Items per page

Supplemental Content

Write to the Help Desk